Return Peptide Library
Retatrutide
ALevel 1 evidenceRetatrutide
GLP-1 and incretin receptor agonists
Basic Information
Categories
GIP/GLP-1/Glucagon Triple Receptor Agonist
Overview
Eli Lilly's triple agonist: Phase III TRIUMPH-4 showed 23.7% weight loss.
Efficacy Rating
Weight loss, in research, GLP-1
Evidence Level
Grade A
Evidence Type
No data available
Confidence
No data available
China Regulatory Status
Cosmetic Ingredient Directory
No data available
Food/Supplements
No data available
Medicine
No data available
Similar Peptide Recommendations
Survodutide
Survodutide
AGLP-1 and incretin receptor agonists
Weight loss, in research, GLP-1
Dulaglutide
Dulaglutide
AGLP-1 and incretin receptor agonists
Weight loss, metabolic health, FDA-approved
Liraglutide
Liraglutide
AGLP-1 and incretin receptor agonists
Weight loss, metabolic health, FDA-approved
MariTide
MariTide
AGLP-1 and incretin receptor agonists
Bispecific, GLP-1 Agonist, GIPR Antagonist
Disclaimer
The content on this platform is for educational and informational purposes only and does not constitute medical advice, formulation guidance, or a guarantee of regulatory compliance. All efficacy claims are labeled with their evidence level; please consult a professional before making any decisions.